ORAL PROPHYLAXIS WITH BCX7353 REDUCES HAE ATTACK RATES AND IS WELL-TOLERATED: APEX-2 STUDY RESULTS

被引：1
|
作者：
Zuraw, B.
Lumry, W.
Banerji, A.
Aygoren-Pursun, E.
Bernstein, J.
Johnston, D.
Christiansen, S.
Riedl, M.
Cicardi, M.
Maurer, M.
Cornpropst, M.
Dobo, S.
Iocca, H.
Nagy, E.
Murray, S.
Collis, P.
Sheridan, W.
机构：
来源：
ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY | 2019年 / 123卷 / 05期
关键词：
D O I：
10.1016/j.anai.2019.08.254
中图分类号：
R392 [医学免疫学];
学科分类号：
100102 ;
摘要：
P150
引用
收藏
页码：S27 / S27
页数：1
相关论文
共 32 条
  • [1] Oral Prophylaxis with Berotralstat (BCX7353) Reduces Use of Standard of Care (SOC) On-demand Medication in Patients with Hereditary Angioedema (HAE): APeX-2 Study Results
    Bernstein, Jonathan
    Zuraw, Bruce
    Aygoren-Pursun, Emel
    Li, Huamin
    Busse, Paula
    Johnston, Douglas
    Maurer, Marcus
    Lumry, William
    Riedl, Marc
    Jacobs, Joshua
    Sitz, Karl
    Gagnon, Remi
    Clemons, Desiree
    Dobo, Sylvia
    Nagy, Eniko
    Murray, Sharon
    Collis, Philip
    Sheridan, William
    Banerji, Aleena
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB106 - AB106
  • [2] SAFETY AND TOLERABILITY OF ONCE-DAILY ORAL KALLIKREIN INHIBITOR BCX7353 IN PHASE 3 APEX-2 HAE STUDY
    Riedl, M.
    Lumry, W.
    Banerji, A.
    Aygoren-Pursun, E.
    Bernstein, J.
    Maurer, M.
    Cicardi, M.
    Christiansen, S.
    Zuraw, B.
    Dobo, S.
    Cornpropst, M.
    Iocca, H.
    Nagy, E.
    Murray, S.
    Collis, P.
    Sheridan, W.
    Johnston, D.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2019, 123 (05) : S28 - S29
  • [3] Relative Reductions in Attack Rate With Prophylactic Berotralstat (BCX7353) in Subjects with Hereditary Angioedema (HAE): Responder Analysis from the APeX-2 Study
    Lumry, William
    Maurer, Marcus
    Zuraw, Bruce
    Banerji, Aleena
    Riedl, Marc
    Johnston, Douglas
    Aygoren-Pursun, Emel
    Jacobs, Joshua
    Gower, Richard
    Wedner, H. James
    Sitz, Karl
    Magerl, Markus
    Cornpropst, Melanie
    Elder, Jennifer
    Iocca, Heather
    Nagy, Eniko
    Murray, Sharon
    Collis, Philip
    Sheridan, William
    Christiansen, Sandra
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : AB105 - AB105
  • [4] Long-term safety and tolerability of Berotralstat (BCX7353) for Hereditary Angioedema (HAE) prophylaxis: APeX-S study results
    Farkas, H.
    Wu, A. Y.
    Kiani, S.
    Reshef, A.
    Stobiecki, M.
    Kinaciyan, T.
    Maurer, M.
    Aygoren-Pursun, E.
    Dix, D.
    Dobo, S.
    Iocca, H.
    Murray, S.
    Sheridan, W. P.
    Peter, J.
    [J]. ALLERGY, 2020, 75 : 58 - 59
  • [5] Long-term effectiveness of berotralstat (BCX7353) for the prophylaxis of hereditary angioedema (HAE) attacks: Results from the APeX-S study
    Reshef, A.
    Maurer, M.
    Kiani, S.
    Wu, A. Y.
    Stobiecki, M.
    Kinaciyan, T.
    Peter, J.
    Aygoren-Pursun, E.
    Cornpropst, M.
    Nagy, E.
    Murray, S.
    Collis, P.
    Farkas, H.
    [J]. ALLERGY, 2020, 75 : 210 - 211
  • [6] Long-term safety and effectiveness of berotralstat (BCX7353) for the prophylaxis of hereditary angioedema (HAE) attacks: Results from the APeX-S study
    Kiani, Sorena
    Wu, Adrian
    Peter, Jonathan
    Reshef, Avner
    Maurer, Marcus
    Stobiecki, Marcin
    Kinaciyan, Tamar
    Aygoeren-Puersuen, Emel
    Best, Jessica
    Cornpropst, Melanie
    Sheridan, William P.
    Farkas, Henriette
    [J]. CLINICAL AND EXPERIMENTAL ALLERGY, 2021, 51 (01): : 172 - 173
  • [7] Randomized Trial of the Efficacy and Safety of Berotralstat (BCX7353) as an Oral Prophylactic Therapy for Hereditary Angioedema: Results of APeX-2 Through 48 Weeks (Part 2)
    Wedner, H. James
    Aygoeren-Puersuen, Emel
    Bernstein, Jonathan
    Craig, Timothy
    Gower, Richard
    Jacobs, Joshua S.
    Johnston, Douglas T.
    Lumry, William R.
    Zuraw, Bruce L.
    Best, Jessica M.
    Iocca, Heather A.
    Murray, Sharon C.
    Desai, Bhavisha
    Nagy, Eniko
    Sheridan, William P.
    Kiani-Alikhan, Sorena
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (06): : 2305 - +
  • [8] Berotralstat (BCX7353) treatment demonstrates robust and durable reduction in the rate of hereditary angioedema (HAE) attacks over 48 weeks of the phase 3 APeX-2 study
    Aygoren-Pursun, E.
    Johnston, D.
    Banerji, A.
    Bernstein, J. A.
    Yang, W. H.
    Fritz, S.
    Zuraw, B.
    Mcneil, D.
    Cornpropst, M.
    Murray, S.
    Nagy, E.
    Collis, P.
    Craig, T.
    [J]. ALLERGY, 2020, 75 : 457 - 458
  • [9] BCX7353: AN EFFECTIVE AND SAFE ORAL PROPHYLAXIS AGAINST ATTACKS OF HEREDITARY ANGIOEDEMA. APEX-1 FINAL RESULTS
    Aygoeren-Puersuen, E.
    Bygum, A.
    Panovska, V. Grivcheva
    Steiner, U.
    Huissoon, A.
    Kinaciyan, T.
    Fain, O.
    Longhurst, H.
    Farkas, H.
    Fang, L.
    Cornpropst, M.
    Clemons, D.
    Dobo, S.
    Maurer, M.
    Cicardi, M.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2017, 119 (05) : E4 - E4
  • [10] RELATIONSHIP OF TARGET CONCENTRATIONS WITH EFFICACY: RESULTS FROM THE APEX-1 STUDY OF BCX7353
    Farkas, H.
    Aygoren-Pursun, E.
    Panovska, V. Grivcheva
    Huissoon, A.
    Kinaciyan, T.
    Murray, S.
    Cornpropst, M.
    Sheridan, W.
    Maurer, M.
    Cicardi, M.
    [J]. ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY, 2018, 121 (05) : S33 - S33
1234